Drug Discovery and Molecular Pharmacology C – DMPC
Begins for upcoming October/November 2022 application deadlines, with first review dates in February/March 2023. It was created as part of CSR’s ENQUIRE process which functions to align study sections with advances in science.
The Drug Discovery and Molecular Pharmacology C (DMPC) study section reviews cancer-related applications focused on the discovery, design, identification, isolation, development of new molecular agents that are potentially useful in cancer therapy of solid tumors and leukemias. Agents may combat cancer by slowing cancer cell growth, hastening cancer cell death, sensitizing cancer cells to other therapies, inhibiting metastasis or angiogenesis, or ameliorating side effects.
Review Dates
Topics
- Discovery of novel anti-cancer agents including small molecule inhibitors, natural products, peptides/proteins/peptidomimetics, repurposed drugs, immunomodulators, and combination regimens.
- Molecular characterization of new anti-cancer agents, including mechanism of action, structural characterization of enzyme-inhibitor complexes, and confirmation of target engagement.
- Optimization and preclinical studies of anti-cancer agents, including medicinal chemistry, hit-to-lead optimization; combination regimens, and early- stage toxicity and PK/PD studies in cellular and animal models.
- Design and development of new molecular entities/ vehicles for targeted delivery of anti- cancer therapeutics (eg, polymers, micelles and nanoparticles)
- Development of methods to test drug efficacy, including cellular, organoids, and animals.
Shared Interests and Overlaps
There are shared interests in drug development with Advancing Therapeutics A (ATA). Applications focused on early stages of drug discovery involving synthesis, validation/optimization of new anti-cancer therapeutic agents and in vivo evaluation of new drugs are reviewed in DMPC. Applications focused on preclinical safety/toxicity that also involve limited late-stage optimization of anti-cancer agents are reviewed in ATA.
There are shared interests in drug design with Chemical Biology & Probes (CBP). Applications that emphasize drug function and anticancer therapeutic potential are reviewed in DMPC. Applications that emphasize drug synthesis with limited biological assessments are reviewed in CBP.
There are shared interests in developing conventional and molecularly targeted agents with Mechanisms of Cancer Therapeutics-A (MCTA). Applications that focus on early stages of drug discovery involving synthesis, validation/ optimization of new anti-cancer therapeutic agents and in vivo evaluation of new drugs are reviewed in DMPC. Applications that focus on mechanistic validation of novel agents at the molecular, cellular, or target tissue level are reviewed in MCTA.
There are shared interests in developing conventional and molecularly targeted agents with Mechanisms of Cancer Therapeutics-B (MCTB). Applications that focus on chemical modification of existing compounds are reviewed in DMPC. Applications that focus on mechanism of action of these compounds at the molecular, cellular, or target tissue level are reviewed in MCTB.
There are shared interests in developing conventional and molecularly targeted agents with Mechanisms of Cancer Therapeutics-C (MCTC). Applications that focus on chemical modification of existing compounds are reviewed in DMPC. Applications that focus on mechanism of action of these compounds at the molecular, cellular, or target tissue level are reviewed in MCTC.
